<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01658384</url>
  </required_header>
  <id_info>
    <org_study_id>CNO-001</org_study_id>
    <nct_id>NCT01658384</nct_id>
  </id_info>
  <brief_title>Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients</brief_title>
  <acronym>CogMS</acronym>
  <official_title>Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinique Neuro-Outaouais</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CogState Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Clinique Neuro-Outaouais</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the effect of Tysabri on cognition in multiple sclerosis&#xD;
      (MS) patients. During a period of 24 months, the study will assess the evolution of cognitive&#xD;
      function in Tysabri treated MS patients using the Symbol Digit Modalities Test (SDMT) and the&#xD;
      CogState battery of tests.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tysabri reduces the relapse frequency, slows progression and preserves cognitive function as&#xD;
      compared to placebo as per the AFFIRM trial. The benefit on relapse rate and progression&#xD;
      appears to be sustained in longer-term studies such as STRATA. In clinical practice however&#xD;
      despite a stable condition on the Expanded Disability Status Scale (EDSS) patients often&#xD;
      complain of cognitive deterioration. It has yet to be shown that Tysabri will prevent&#xD;
      cognitive deterioration after more than 2 years of treatment.&#xD;
&#xD;
      The Symbol Digit Modalities Test (SDMT) is a sensitive and validated test of cognition in MS.&#xD;
      CogState offers a standardized battery of cognitive tests frequently used in clinical&#xD;
      research in the fields of dementia and Parkinson's disease. The CogState battery of tests&#xD;
      consisting of the Detection test (processing speed), Identification test (attention), One&#xD;
      Back test (working memory), International Shopping List test (verbal learning) and the Groton&#xD;
      Maze Learning test (reasoning and problem solving) will further confirm and validate the&#xD;
      results of the Symbol Digit Modalities Test(SDMT) in MS patients as well as examine other&#xD;
      cognitive parameters.&#xD;
&#xD;
      Together the above tests done prospectively can assess the evolution of cognitive function in&#xD;
      Tysabri treated MS patients over the longer term.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>SDMT CogState battery</measure>
    <time_frame>2 years</time_frame>
    <description>Monthly cognitive assessments</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">63</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>cognitive evolution, observational,MS</arm_group_label>
    <description>multiple sclerosis tysabri treated patients</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with multiple sclerosis who are receiving Tysabri per indication.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with multiple sclerosis who are receiving Tysabri per indication and are&#xD;
             willing and able to give an informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are depressed as per the Beck depression questionnaire at screening or at&#xD;
             any time during the study.&#xD;
&#xD;
          -  Patients with cognitive decline from causes other than MS.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fran√ßois H Jacques, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Neuro-Outaouais</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinique Neuro-Outaouais</name>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <zip>J9J 0A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>November 10, 2011</study_first_submitted>
  <study_first_submitted_qc>August 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2012</study_first_posted>
  <last_update_submitted>March 4, 2019</last_update_submitted>
  <last_update_submitted_qc>March 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

